Interleukin-7 Dose-Dependently Restores Parenteral Nutrition–Induced Gut-Associated Lymphoid Tissue Cell Loss but Does Not Improve Intestinal Immunoglobulin A Levels

Abstract

Background: Without enteral nutrition, the mass and function of gut-associated lymphoid tissue (GALT), a center of systemic mucosal immunity, are reduced. Therefore, new therapeutic methods, designed to preserve mucosal immunity during parenteral nutrition (PN), are needed. Our recent study revealed that exogenous interleukin-7 (IL-7; 1 μg/kg twice a day) restores the GALT cell mass lost during intravenous (IV) PN but does not improve secretory immunoglobulin A (IgA) levels. Herein, we studied the IL-7 dose response to determine the optimal IL-7 dose for recovery of GALT mass and function during IV PN. We hypothesized that a high dose of IL-7 would increase intestinal IgA levels, as well as GALT cell numbers. Methods: Male mice (n = 42) were randomized to chow, IL-7-0, IL-7-0.1, IL-7-0.33, IL-7-1 and IL-7-3.3 groups and underwent jugular vein catheter insertion. The IL-7 groups were fed a standard PN solution and received IV injections of normal saline (IL-7-0), 0.1, 0.33, 1, or 3.3 μg/kg of IL-7 twice a day. The chow group was fed chow ad libitum. After 5 days of treatment, the entire small intestine was harvested and lymphocytes were isolated from Peyer's patches (PPs), intraepithelial (IE) spaces, and the lamina propria (LP). The lymphocytes were counted and phenotypes determined by flow cytometry (αβTCR, γδTCR, CD4, CD8, B cell). IgA levels of small intestinal washings were also examined using ELISA (enzyme-linked immunoabsorbent assay). Results: IL-7 dose-dependently increased total lymphocyte numbers in PPs and the LP. The number of lymphocytes harvested from IE spaces reached a plateau at 1 μg/kg of IL-7. There were no significant differences in any phenotype percentages at any GALT sites among the groups. IgA levels of intestinal washings were significantly higher in the chow group than in any of the IL-7 groups, with similar levels in all IL-7 groups. Conclusions: Exogenous IL-7 dose-dependently reverses PN-induced GALT cell loss, with no major changes in small intestinal IgA levels. IL-7 treatment during PN appears to have beneficial effects on gut immunity, but other therapeutic methods are needed to restore secretory IgA levels.

Mice were fed a PN solution and received IV injections of normal saline, 0.1, 0.33, 1, or 3.3 μg/kg of interleukin-7 (IL-7) twice a day. After 5 days’ treatment, IL-7 dose-dependently restored PN-induced gut-associated lymphoid tissue cell loss but did not improve intestinal immunoglobulin A levels.

Get full access to this article

View all access options for this article.

References

Kelsall B, Strober W. Gut-associated lymphoid tissue. In: Ogra PL, Mestecky J, Lamm ME, Strober W, Bienenstock J, McGhee JR, eds. Mucosal Immunology. San Diego, CA: Academic Press; 1999:293– 317.

Johnson CD, Kudsk KA. Nutrition and intestinal mucosal immunity.Clin Nutr. 1999;18:337– 344.

Kudsk KA, Li J, Renegar KB. Loss of upper respiratory tract immunity with parenteral feeding. Ann Surg. 1996 ;223:629– 635.

Kudsk KA. Current aspects of mucosal immunology and its influence by nutrition. Am J Surg. 2002 ;183:390– 398.

Fukatsu K, Sakamoto S, Hara E, et al. Gut ischemia-reperfusion affects gut mucosal immunity: a possible mechanism for infectious complications after severe surgical insults. Crit Care Med. 2006 ;34:182– 187.

Hassoun HT, Kone BC, Mercer DW, Moody FG, Weisbrodt NW, Moore FA. Post-injury multiple organ failure: the role of the gut. Shock. 2001 ;15:1– 10.

Buzdon MM, Napolitano LM, Shi HJ, Ceresoli DM, Rauniya R, Bass BL. Femur fracture induces site-specific changes in T-cell immunity. J Surg Res. 1999;82:201– 208.

Li J, Kudsk KA, Gocinski B, Dent D, Glezer J, Langkamp-Henken B. Effects of parenteral and enteral nutrition on gut-associated lymphoid tissue.J Trauma. 1995;39:44– 51.

King BK, Li J, Kudsk KA. A temporal study of TPN-induced changes in gut-associated lymphoid tissue and mucosal immunity. Arch Surg. 1997 ;132:1303– 1309.

10.

Okamoto K, Fukatsu K, Ueno C, et al. T lymphocyte numbers in human gut associated lymphoid tissue are reduced without enteral nutrition.JPEN J Parenter Enteral Nutr. 2005 ;29:56– 58.

11.

Kudsk KA, Croce MA, Fabian TC, et al. Enteral versus parenteral feeding: effects on septic morbidity after blunt and penetrating abdominal trauma. Ann Surg. 1992;215:503– 511.

12.

Moore FA, Feliciano DV, Andrassy RJ, et al. Early enteral feeding, compared with parenteral, reduces postoperative septic complications: the results of a meta-analysis. Ann Surg. 1992 ;216:172– 183.

13.

Bilenker M, Roberts AI, Brolin RE, Ebert EC. Interleukin-7 activates intestinal lymphocytes. Dig Dis Sci. 1995 ;40:1744– 1749.

14.

Spahn TW, Kucharzik T. Modulating the intestinal immune system: the role of lymphotoxin and GALT organs. Gut. 2004 ;53:456– 465.

15.

Yang H, Tazuke Y, Ko K, Teitelbaum DH. TPN administration alters intestinal epithelial cell derived IL-7: potential mechanism for alteration in intraepithelial lymphocyte changes [abstract]. JPEN J Parenter Enteral Nutr. 2003;27:S6 . Abstract 011.

16.

Fukatsu K, Moriya T, Maeshima Y, et al. Exogenous IL-7 affects gut associated lymphoid tissue in mice receiving total parenteral nutrition.Shock. 2005;24:541– 546.

17.

Sitren HS, Heller PA, Bailey LB, Cerda JJ. Total parenteral nutrition in the mouse: development of a technique. JPEN J Parenter Enteral Nutr. 1983;7:582– 586.

18.

Mahaffey SM, Copeland III EM, Talbert JL, Baumgartner TG, Sitren HS. Further studies of a technique for total parenteral nutrition in the mouse. Nutr Res. 1985;5:1121– 1130.

19.

Fry TJ, Mackall CL. The many faces of IL-7: from lymphopoiesis to peripheral T cell maintenance. J Immunol. 2005 ;174:6571– 6576.

20.

Monroe JG, Allman D. Keeping track of pro-B cells: a new model for the effects of IL-7 during B cell development. Eur J Immunol. 2004 ;34:2642– 2646.

21.

Wu Y, Kudsk KA, DeWitt RC, Tolley EA, Li J. Route and type of nutrition influence IgA-mediating intestinal cytokines. Ann Surg. 1999;229:662– 667.

22.

Watanabe M, Ueno Y, Yajima T, et al. Interleukin 7 is produced by human intestinal epithelial cells and regulates the proliferation of intestinal mucosal lymphocytes. J Clin Invest. 1995 ;95:2945– 2953.

23.

Yada S, Nukina H, Kishihara K, et al. IL-7 prevents both caspase-dependent and -independent pathways that lead to the spontaneous apoptosis of i-IEL. Cell Immunol. 2001 ;208:88– 95.

24.

Yang H, Spencer AU, Teitelbaum DH. Interleukin-7 administration alters intestinal intraepithelial lymphocyte phenotype and function in vivo. Cytokine. 2005 ;31:419– 428.

25.

Borger P, Kauffman HF, Postma DS, Vellenga E. IL-7 differentially modulates the expression of IFN-gamma and IL-4 in activated human T lymphocytes by transcriptional and post-transcriptional mechanisms. J Immunol. 1996;156:1333– 1338.

26.

Laky K, Lefrancois L, Lingenheld EG, et al. Enterocyte expression of interleukin 7 induces development of gammadelta T cells and Peyer's patches. J Exp Med. 2000 ;191:1569– 1580.

27.

Ikeda S, Kudsk KA, Fukatsu K, et al. Enteral feeding preserves mucosal immunity despite in vivo MAdCAM-1 blockade of lymphocyte homing. Ann Surg. 2003;237:677– 685.